The head of Cipla, $ 325-million Indian pharmaceutical company and seller of cheap AIDS drugs in South Africa, have to decide what to do with the future of Cipla's. With India ready to comply with international patents in two years, much of the product line Cipla could become unsaleable (given that it is based on the product is protected by patents in developed countries). Describes the role of a global pharmaceutical Cipla forcing companies to reduce the price of AIDS drugs. "Hide
by Rohit Deshpande, Laura Winig Source: Harvard Business School 21 pages. Publication Date: June 23, 2003. Prod. #: 503085-PDF-ENG
Related Case Solutions & Analyses:
Ganesh Natarajan: Leading Innovation and Organizational Change at Zensar (B)
Endo Pharmaceuticals (A): From LBO to …
Hindustan Lever (B): The Reality Check
The Queen vs Dudley and Stephens (1884) (The Lifeboat Case)
oDesk: Changing How the World Works
Ratios Tell A Story 2007
Business Finance
Informal Networks: The Company behind the Chart
Gordon Biersch
Alan Kendricks at Cardiology Associates
